Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 865, Issue 1-2, 2008, Pages 91-98

  Varanasi, Kanthi Kiran V S ^a   Sridhar, V ^a   Potharaju, Suresh ^a   Shraddha, R ^a   Sivakumar, S P N ^a   Kanaga Sabapathi, S ^a   Satheeshmanikandan, T R S ^a   Swaroop Kumar, V V S ^a  

^a Glenmark Pharmaceuticals Limited   (India)

Author keywords

3,4 Dehydro cilostazol; Bioanalytical; Cilostazol; LC MS MS; Nateglinide; Rat plasma

Indexed keywords

BIOANALYTICALS; CILOSTAZOL; NATEGLINIDE;

BIOASSAY; INSULIN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

BIOMEDICAL ENGINEERING;

3,4 DEHYDROCILOSTAZOL; ACETONITRILE; AMMONIUM ACETATE; CILOSTAZOL; DRUG METABOLITE; NATEGLINIDE; REPAGLINIDE; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG STABILITY; FLOW RATE; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; WISTAR RAT;

ANIMALS; CHROMATOGRAPHY, LIQUID; CYCLOHEXANES; PHENYLALANINE; RATS; RATS, WISTAR; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TETRAZOLES;

RATTUS; RATTUS NORVEGICUS;

EID: 41349102721     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.02.013     Document Type: Article

References (20)

1. Dunn C.J., and Faulds D. Drugs 60 (2000) 607
2. Hu S. Eur. J. Pharmacol. 442 (2002) 163
3. Hu S., Boettcher B.R., and Dunning B.E. Diabetologia 46 Suppl. 1 (2003) M37
4. Fujitani S., Ikenoue T., Akiyoshi M., Maki T., and Yada T. Metabolism 45 (1996) 184
5. Keilson L., Mather S., Walter Y.H., Subramanian S., and McLeod J.F. J. Clin. Endocrinol. Metab. 85 (2000) 1081
6. Weaver M.L., Orwig B.A., Rodriguez L.C., et al. Drug. Metab. Dispos. 29 (2001) 415
7. Chapman T.M., and Goa K.L. Am. J. Cardiovasc. Drugs 3 (2003) 117
8. Schror K. Diabetes Obes. Metab. 4 Suppl. 2 (2002) S14
9. Abbas R., Chow C.P., Browder N.J., et al. Hum. Exp. Toxicol. 19 (2000) 178
10. Akiyama H., Kudo S., and Shimizu T. Arzneimittelforschung 35 (1985) 1133
11. Bramer S.L., Tata P.N., Vengurlekar S.S., and Brisson J.H. J. Pharm. Biomed. Anal. 26 (2001) 637
12. Akiyama H., Kudo S., Odomi M., and Shimizu T. J. Chromatogr. 338 (1985) 456
13. Fu C.J., Tata P.N., Okada K., Akiyama H., and Bramer S.L. J. Chromatogr. B Biomed. Sci. Appl. 728 (1999) 251
14. Tata P.N., Fu C.H., and Bramer S.L. J. Pharm. Biomed. Anal. 24 (2001) 381
15. Tata P.N., Fu C.H., Browder N.J., Chow P.C., and Bramer S.L. J. Pharm. Biomed. Anal. 18 (1998) 441
16. Bauer S., Stormer E., Kirchheiner J., et al. J. Pharm. Biomed. Anal. 31 (2003) 551
17. Choudhury S., Hirschberg Y., Filipek R., Lasseter K., and McLeod J.F. J. Clin. Pharmacol. 40 (2000) 634
18. Ono I., Matsuda K., and Kanno S. J. Chromatogr. B Biomed. Appl. 678 (1996) 384
19. Ono I., Matsuda K., and Kanno S. J. Chromatogr. B Biomed. Sci. Appl. 692 (1997) 397
20. Wang M., and Miksa I.R. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 856 (2007) 318